SCHEMBL136872

SCHEMBL136872

CCCCCCCCCC1OCCO1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.62
EPHX1 P07099 1/20 0.58
SPHK1 Q9NYA1 7/20 0.46
SPHK2 Q9NRA0 6/20 0.46
PRKD3 O94806 2/20 0.44
PRKCG P05129 2/20 0.44
PRKCB P05771 2/20 0.44
PRKCA P17252 2/20 0.44
PRKCH P24723 2/20 0.44
PRKCI P41743 2/20 0.44
PRKCE Q02156 2/20 0.44
PRKCQ Q04759 2/20 0.44
PRKCZ Q05513 2/20 0.44
PRKCD Q05655 2/20 0.44
PRKD1 Q15139 2/20 0.44
TDP1 Q9NUW8 1/20 0.42
ENPP2 Q13822 1/20 0.41
LPAR2 Q9HBW0 1/20 0.41
TSHR P16473 1/20 0.40
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL413367 1.00 ALDH1A1 (0.62) ALDH1A1EPHX1SPHK1SPHK2PRKD3
SCHEMBL16995925 1.00 ALDH1A1 (0.62) ALDH1A1EPHX1SPHK1SPHK2PRKD3
SCHEMBL28757032 1.00 ALDH1A1 (0.62) ALDH1A1EPHX1SPHK1SPHK2PRKD3
SCHEMBL873108 1.00 ALDH1A1 (0.62) ALDH1A1EPHX1SPHK1SPHK2PRKD3
SCHEMBL2102930 1.00 ALDH1A1 (0.62) ALDH1A1EPHX1SPHK1SPHK2PRKD3
SCHEMBL1668988 1.00 ALDH1A1 (0.62) ALDH1A1EPHX1SPHK1SPHK2PRKD3
SCHEMBL10514828 1.00 ALDH1A1 (0.62) ALDH1A1EPHX1SPHK1SPHK2PRKD3
SCHEMBL14779258 1.00 ALDH1A1 (0.62) ALDH1A1EPHX1SPHK1SPHK2PRKD3
SCHEMBL15560286 1.00 ALDH1A1 (0.62) ALDH1A1EPHX1SPHK1SPHK2PRKD3
SCHEMBL27821359 1.00 ALDH1A1 (0.62) ALDH1A1EPHX1SPHK1SPHK2PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12636262-B2 Process for the preparation of topical formulation Neuheit Pharma Technologies Pvt. Ltd. (IN) 2026-05-26 US claimed
US-12527729-B2 Minoxidil adjuvant therapies CARING BRANDS, INC. (US) 2026-01-20 US claimed
US-20240224994-A1 INSECT REPELLANT FORMULATION AND METHOD OF USING SAME UNITED INDUSTRIES CORPORATION 2024-07-11 US claimed
US-20230404886-A1 MINOXIDIL ADJUVANT THERAPIES Jupiter Wellness, Inc. (US) 2023-12-21 US claimed
US-11730831-B2 Imaging agents and methods of using the same SICREATIONS, LLC (US) 2023-08-22 US claimed
WO-2022251534-A1 INSECT REPELLENT FORMULATION AND METHOD OF USING SAME UNITED INDUSTRIES CORPORATION (US) 2022-12-01 WO claimed
US-20220265577-A1 PROCESS FOR THE PREPARATION OF ANTHRAQUINONE TOPICAL FORMULATION NEUHEIT PHARMA TECHNOLOGIES PVT. LTD (IN) 2022-08-25 US claimed
CN-114404424-A A pharmaceutical composition for treating alopecia, and its preparation method 硬核医药科技(上海)有限公司 2022-04-29 CN claimed
US-20200323998-A1 IMAGING AGENTS AND METHODS OF USING THE SAME SICREATIONS, LLC 2020-10-15 US claimed
WO-2020198534-A1 IMAGING AGENTS AND METHODS OF USING THE SAME SICREATIONS, LLC (US) 2020-10-01 WO claimed
CN-1229696-A Catalyst for conversion of ethylene into light alpha olefins INST FRANCAIS DU PETROLE (FR) 1999-09-29 CN claimed
US-5942545-A Composition and method for treating penile erectile dysfunction MACROCHEM CORPORATION (US) 1999-08-24 US claimed
WO-1999009954-A1 NON-STEROIDAL ANTIINFLAMMATORY DRUG FORMULATIONS FOR TOPICAL APPLICATION TO THE SKIN MACROCHEM CORPORATION (US) 1999-03-04 WO claimed
CN-1195580-A Improved catalytic composition and process for converting ethylene to light alpha olefins INST FRANCAIS DU PETROLE (FR) 1998-10-14 CN claimed
EP-0552879-B1 Improved iontophoretic administration of drugs MACROCHEM CORP (US) 1998-08-19 EP claimed
EP-0578541-B1 Process for the preparation of light alpha-olefines by oligomerisation of ethylene INST FRANCAIS DU PETROLE (FR) 1997-12-03 EP claimed
EP-0728462-A2 Cosmetic method and composition for treating hair loss MacroChem Corporation (US) 1996-08-28 EP claimed
US-5496783-A CATALYSIS WITH MIXTURE OF ZIRCONIUM COMPOUND, ACETAL OR KETAL, AND ORGANOALUMINUM BROMIDE OR CHLORIDE INSTITUT FRANCAIS DU PETROLE (FR) 1996-03-05 US claimed
US-5345023-A Zirconium coordination catalysts with acetals and ketals INSTITUT FRANCAIS DU PETROLE (FR) 1994-09-06 US claimed
EP-0552879-A1 Improved iontophoretic administration of drugs MACROCHEM CORPORATION (US) 1993-07-28 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12527729-B2 Minoxidil adjuvant therapies RXRA, RXRB, RXRG ALDH1A1 2373/4885EPHX1 2134/4885SPHK1 995/4885
US-20220265577-A1 PROCESS FOR THE PREPARATION OF ANTHRAQUINONE TOPICAL FORMULATION RFTN1, DSTN, TREH ALDH1A1 2327/4885EPHX1 1111/4885SPHK1 312/4885
US-12636262-B2 Process for the preparation of topical formulation LRAT, LIPA, DSG1 ALDH1A1 3989/4885EPHX1 962/4885SPHK1 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.